I am an associate professor in the department of Microbiology-Infectiology and Immunology, at the Laval University School of Medicine, and a member of the Infectious Diseases and Immunology Axis of the CHUQ Research Center, CHUL Pavilion.

I did my PhD at McGill University in molecular genetics and my post-doctoral studies at Thomas Jefferson University (Philadelphia) in cancer, during which I cloned two new genes that code for C-type lectin receptors. During my subsequent post-doctoral work at Laval University, my research focused on neutrophil biology, and specifically on signaling. The current research in my laboratory brings together these three fields of research, namely, genetics, C-type lectin receptors, and innate immunity.

The overall goal of the research in my laboratory is to further our understanding of the immunopathogenesis of two types of arthritis, namely rheumatoid arthritis and gout. Arthritis refers to a group of diseases that affect the joints and cause pain and inflammation. There are over 100 types of arthritis. Although drugs are available to treat different types of arthritis, many medications are associated with secondary side effects, and some patients don’t respond to available drugs. To address this unmet need, we must gain more insight into the pathogenesis of these diseases to develop more effective and less toxic drugs.

Our research revealed that the C-type lectin receptor known as Clec12A is involved in the pathogenesis of rheumatoid arthritis and gout. This discovery provides insight into one of the mechanisms through which the immune system is deregulated in these diseases. Clec12A is an inhibitory receptor that is expressed by the innate immune cells of the myeloid lineage, such as neutrophils and monocytes. It is also expressed by dendritic cells. Our current working hypothesis is that in gout and rheumatoid arthritis, the Clec12A inhibitory pathway is not fully functional, causing myeloid cells to be more easily activated.

We use a multidisciplinary approach to gain insight into how Clec12A works to determine its contribution to the pathogenesis of arthritis, with the goal of eventually transferring our findings to clinical practice. The molecular and cellular biology tools we use will shed light on how Cle12A dampens the activation of immune cells. To complement this line of research, the more clinical aspect of our Clec12A project involves the analysis of patient samples to better understand the potential role of this inhibitor in chronic inflammatory diseases (e.g.: gout and rheumatoid arthritis).

Another aspect of our research involves the development of a new anti-inflammatory drug to treat gout, using a rational drug design approach. This new drug may also have the ability to dampen inflammation in patients suffering from other inflammatory diseases.

In summary, our research aims to further our understanding of the pathogenesis of gout and rheumatoid arthritis, identify biomarkers for these diseases, as well as develop a new anti-inflammatory drug that is less toxic and more potent than those used to currently treat gout and other chronic inflammatory diseases. The results of this research will also shed light on the role of Clec12A in other chronic inflammatory diseases, since the Clec12A pathways also seem to be dysregulated in Crohn’s disease.

2705, boulevard Laurier
Québec, Québec
Canada G1V 4G2

Latest news

Data not available

38 entries « 2 of 4 »

Zhao C, Hui W, Fernandes MJ, Poubelle PE, Bourgoin SG

Lysophosphatidic acid-induced IL-8 secretion involves MSK1 and MSK2 mediated activation of CREB1 in human fibroblast-like synoviocytes.

Journal Article

Biochem Pharmacol, 90 (1), pp. 62-72, 2014, ISSN: 0006-2952.

Abstract | Links:

Roy C, Gagne V, Fernandes MJ, Marceau F

High affinity capture and concentration of quinacrine in polymorphonuclear neutrophils via vacuolar ATPase-mediated ion trapping: comparison with other peripheral blood leukocytes and implications for the distribution of cationic drugs.

Journal Article

Toxicol Appl Pharmacol, 270 (2), pp. 77-86, 2013, ISSN: 0041-008X.

Abstract | Links:

Gagne V, Marois L, Levesque JM, Galarneau H, Lahoud MH, Caminschi I, Naccache PH, Tessier P, Fernandes MJ

Modulation of monosodium urate crystal-induced responses in neutrophils by the myeloid inhibitory C-type lectin-like receptor: potential therapeutic implications.

Journal Article

Arthritis Res Ther, 15 (4), pp. R73, 2013, ISSN: 1478-6354.

Abstract | Links:

Michou L, Cornelis F, Levesque JM, Bombardieri S, Balsa A, Westhovens R, Barrera P, Alves H, van de Putte L, Migliorini P, Bardin T, Petit-Teixeira E, Fernandes MJ

A genetic association study of the CLEC12A gene in rheumatoid arthritis.

Journal Article

Joint Bone Spine, 79 (5), pp. 451-6, 2012, ISSN: 1297-319X.

Abstract | Links:

Bourgoin SG, Zhao C, Fernandes MJ

Targeting the metabolism and receptors of sphingosine-1- phosphate for the treatment of rheumatoid arthritis

Book Chapter

A, Lemmey (Ed.): Rheumatoid Arthritis - Treatment, pp. 195-210, Rijeka, InTech, 2012, ISBN: 978-953-307-850-2 .

| Links:

Paramasivam M, Sarkeshik A, Yates JR 3rd, Fernandes MJ, McCollum D

Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor.

Journal Article

Mol Biol Cell, 22 (19), pp. 3725-33, 2011, ISSN: 1059-1524.

Abstract | Links:

Zhao C, Sardella A, Chun J, Poubelle PE, Fernandes MJ, Bourgoin SG

TNF-alpha promotes LPA1- and LPA3-mediated recruitment of leukocytes in vivo through CXCR2 ligand chemokines.

Journal Article

J Lipid Res, 52 (7), pp. 1307-18, 2011, ISSN: 0022-2275.

Abstract | Links:

Marois L, Vaillancourt M, Pare G, Gagne V, Fernandes MJ, Rollet-Labelle E, Naccache PH

CIN85 modulates the down-regulation of Fc gammaRIIa expression and function by c-Cbl in a PKC-dependent manner in human neutrophils.

Journal Article

J Biol Chem, 286 (17), pp. 15073-84, 2011, ISSN: 0021-9258.

Abstract | Links:

Hoemann CD, Chen G, Marchand C, Tran-Khanh N, Thibault M, Chevrier A, Sun J, Shive MS, Fernandes MJ, Poubelle PE, Centola M, El-Gabalawy H

Scaffold-guided subchondral bone repair: implication of neutrophils and alternatively activated arginase-1+ macrophages.

Journal Article

Am J Sports Med, 38 (9), pp. 1845-56, 2010, ISSN: 0363-5465.

Abstract | Links:

Gagne V, Moreau J, Plourde M, Lapointe M, Lord M, Gagnon E, Fernandes MJ

Human angiomotin-like 1 associates with an angiomotin protein complex through its coiled-coil domain and induces the remodeling of the actin cytoskeleton.

Journal Article

Cell Motil Cytoskeleton, 66 (9), pp. 754-68, 2009, ISSN: 0886-1544.

Abstract | Links:

38 entries « 2 of 4 »
Signaler des ajouts ou des modifications

Active projects

  • Caractérisation de la viabilité et de la fonction des granulocytes destinés à la transfusion, Partenariat, MITACS Inc., Accélération Québec (MITACS/MEIE), from 2019-09-15 to 2021-11-14
  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31

Recently finished projects

  • A comprehensive analysis of low-density neutrophils in cystic fibrosis : a functional biomarker study, Subvention, Fonds de recherche du Québec - Santé, from 2020-01-01 to 2020-12-31
  • Assessment of the Quality of Granulocyte Concentrates to Optimise their use in Transfusion Therapy., Subvention, Société canadienne du sang, from 2018-12-01 to 2019-11-30
  • Centre de recherche en arthrite de l'Université Laval, Subvention, Institutionnel - BDR, BDR - Entités de recherche en émergence, from 2019-01-01 to 2020-01-31
  • Développement d'une nouvelle drogue anti-inflammatoire qui est moins toxique et plus efficace que la colchicine , Subvention, Fondation du CHU de Québec, from 2020-06-09 to 2021-03-31
  • Évaluation des neutrophiles de faible densité en tant que biomarqueurs et modulateurs de la fonction pulmonaire et de la progression de la fibrose kystique., Subvention, Le Grand Défi Pierre Lavoie, Subvention pour projet de recherche sur une maladie héréditaire orpheline, from 2018-10-01 to 2019-09-30
  • The characterization of MICL, a novel negative regulator of the immune response in arthritis., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2015-07-01 to 2020-06-30
  • The development of a novel anti-inflammatory drug to treat gout, Subvention, Fondation du CHU de Québec, from 2018-04-09 to 2020-03-31
Data provided by the Université Laval research projects registery